Frontline therapy with Tevimbra plus chemotherapy confirmed promising efficacy and manageable security in superior gastric/GEJ most cancers.Amongst sufferers with superior, HER2-negative, mismatch repair-proficient...
On the 2025 ASCO Gastrointestinal Cancers Symposium, investigators, equivalent to Dr. Filippo Pietrantonio, shared knowledge on the OrigAMI-1 trial which assessed Rybrevant (amivantamab)...
The section 3 CABINET trial demonstrated that Cabometyx (cabozantinib) considerably improved median progression-free survival (PFS) in contrast with placebo in sufferers with superior...
